<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809223</url>
  </required_header>
  <id_info>
    <org_study_id>KHSWKH902007</org_study_id>
    <nct_id>NCT01809223</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV</brief_title>
  <acronym>SHINY</acronym>
  <official_title>The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Biotech Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Kanghong Biotech Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is design to evaluate the effect of conbercept therapy on visual acuity and
      anatomic outcomes compared to sham injection and durability of response observed in subjects
      with choroid neovascularization secondary to pathological myopia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change from baseline of visual acuity</measure>
    <time_frame>3-month</time_frame>
    <description>to compare the mean change from baseline of best-corrected visual acuity (BCVA) between conbercept treatment group and sham injection group at month 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline of anatomical features</measure>
    <time_frame>3-month</time_frame>
    <description>to compare the difference of mean change from baseline of CRT, CNV size and lesion size between conbercept treatment group and sham injection group at month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline of visual acuity</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate the mean change from baseline of BCVA of two groups from month 1 to month 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of conbercept</measure>
    <time_frame>3-month and 9-month</time_frame>
    <description>to evaluate the incidence of AEs (ocular or non-ocular) of two groups at month 3 and 9</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Choroid Neovascularization Secondary to Degenerative Myopia</condition>
  <arm_group>
    <arm_group_label>conbercept treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham injection group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conbercept, Fixed</intervention_name>
    <description>intravitreal injection of 0.5 mg conbercept per month, fixed injection</description>
    <arm_group_label>conbercept treatment group</arm_group_label>
    <arm_group_label>sham injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conbercept, PRN</intervention_name>
    <description>intravitreal injection of 0.5 mg conbercept as need, PRN</description>
    <arm_group_label>conbercept treatment group</arm_group_label>
    <arm_group_label>sham injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham injection</intervention_name>
    <description>sham intravitreal injection per month, fixed injection</description>
    <arm_group_label>sham injection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients give fully informed consent and are willing and able to comply with all study
             procedures.

          2. In the study eye:

               -  Myopia of equal to or greater than -6.00D,and axial length ≥26.5mm.

               -  Diagnosis of active subfoveal, juxafoveal, or extrafoveal CNV secondary to high
                  myopia.

               -  Visual impairment due to CNV secondary to high myopia.

               -  BCVA score ≥24 and ≤73 ETDRS letters (approximately 20/40~ 20/320 Snellen
                  equivalent).

               -  Ocular media of sufficient quality to obtain fundus and OCT images.

          3. The BCVA score of fellow eyes ≥ 19 ETDRS letters (approximately 20/400 Snellen
             equivalent)

        Exclusion Criteria:

          1. Current vitreous hemorrhage in either eye.

          2. Intraocular treatment with corticosteroids within last 3 months or periocular
             treatment with corticosteroids within last month in the study eye.

          3. Active infectious ocular inflammation in either eye.

          4. Fibrosis or atrophy involving the center of foveal in the study eye.

          5. Any concurrent intraocular condition in the study eye that, in the opinion of
             investigator, could either require medical or surgical intervention during the study
             period to prevent or treat visual loss that might result from that condition.

          6. The lesion size ≥30 mm2 in the study eye.

          7. Any ocular disorder in the study eye that, in the opinion of the investigator, may
             confound interpretation of the study results.

          8. Uncontrolled glaucoma or cup/disk ratio &gt; 0.8 in the study eye.

          9. Aphakia (excluding artificial lens) in the study eye.

         10. Serious amblyopia and amaurosis in the fellow eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren hospital affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daping Hospital, Research Institute of Surgery Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan General Hospital of Guangzhou Military</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuxi No.2 People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmologic Hospital of Qingdao</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Eye Hospital of WMC</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2013</study_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Myopia, Degenerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

